Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa
Launched by AMICUS THERAPEUTICS · May 16, 2017
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
Epidermolysis bullosa (EB) is a rare, often severe genetic disorder characterized by mechanical fragility and blistering or erosion of the skin, mucosa, or epithelial lining of other organs, in response to little or no apparent trauma.
EB is chronic, potentially disfiguring, and in some cases fatal. Patients with EB have painful wounds and blisters that can lead to infection and scarring. There are many genetic and symptomatic variations of EB, but all forms share the common symptom of fragile skin that blisters and tears, sometimes from the slightest friction or trauma. There is currently...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Confirmed diagnosis of EB including subtype
- • Resident of the US
- • Informed Consent
- • Patient must be 18 years or older
- • If the survey is done by a caregiver, they must be a parent or legal guardian and must be 18 years or older to answer on behalf of a patient under 18 years or on behalf of a patient 18 years or older who is unable to answer for themselves.
- • Must participate in and complete a one hour telephone interview
- Exclusion Criteria:
- • Patient failing to meet the inclusion criteria above
About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company dedicated to developing innovative therapies for rare and orphan diseases, particularly those caused by genetic mutations. With a focus on lysosomal storage disorders, Amicus leverages advanced protein engineering and gene therapy approaches to create treatment options that address unmet medical needs. Committed to patient-centric research, the company collaborates with healthcare professionals and patient advocacy groups to ensure that its clinical trials are designed to deliver meaningful outcomes. Through its robust pipeline and dedication to scientific excellence, Amicus Therapeutics aims to enhance the quality of life for individuals affected by these complex conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cranbury, New Jersey, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials